Liquid biopsy: current technology and clinical applications
Abstract Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fl...
Main Authors: | Mina Nikanjam, Shumei Kato, Razelle Kurzrock |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-022-01351-y |
Similar Items
-
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01) -
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology
by: Bonnita Werner, et al.
Published: (2022-03-01) -
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care
by: Inah Marie C. Aquino, et al.
Published: (2024-03-01) -
Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
by: Patricia Mondelo-Macía, et al.
Published: (2021-01-01)